NasdaqGS:ZBIOBiotechs
Zenas BioPharma (ZBIO): Does This $300 Million Raise Clarify or Complicate Its Funding Strategy?
In late March 2026, Zenas BioPharma completed a US$100,000,000 follow-on equity offering at US$20 per share and a US$200,000,000 issue of 2.50% senior unsecured convertible notes due April 1, 2032.
This combined US$300,000,000 capital raise meaningfully reshapes the company’s funding profile, balancing immediate cash needs with future dilution through convertibles.
We’ll now examine how this sizeable mix of equity and convertible debt financing influences Zenas BioPharma’s investment...